HARBIN, China, May 27 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company")(Nasdaq: CSKI), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), today announced that its Tian Long Pharmaceutical Company ("Tian Long") subsidiary
According to the National Medicine Administration Law of the PRC, all pharmaceutical manufacturers are required to renew their GMP Certificates every five years. SFDA's examination committee visited Tian Long in April to review its supply chain management practices, including quality control system test, inspect its GMP management process, production records for its five production lines, quality test record and laboratory management.
"Given the extensive scope of the inspection and examination, we are very proud to pass the examination in just one round and successfully renewed the GMP Certificate for Tian Long," said Mr. Yan-qing Liu, Chairman and CEO of China Sky One Medical. "China Sky One Medical has built a solid track record of adhering to the highest quality control standards, thanks to our talented and dedicated executives and professional teams in the quality control and production departments."
About China Sky One Medical, Inc.
China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company ("TDR"), Harbin First Bio-Engineering Company Limited ("First"), Heilongjiang Tianlong Pharmaceutical, Inc. ("Tianlong") and Peng Lai Jin Chuang Pharmaceutical Company ("Jin Chuang") the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit http://www.skyonemedical.com .
Safe Harbor Statement
Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding the renewal of GMP Certificate. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.
For more information, please contact: China Sky One Medical, Inc. Mr. Stanley Hao, CFO Tel: +86-451-8703-2617 Email: firstname.lastname@example.org Investor Relations Contact: CCG Investor Relations Ms. Lei Huang, Account Manager Tel: +1-646-833-3417 Email: email@example.com Ms. Mabel Zhang, Vice President Tel: +1-310-954-1353 Email: firstname.lastname@example.org Web: http://www.ccgirasia.com
SOURCE China Sky One Medical, Inc.
Subscribe to our Free Newsletters!
Learn the basics about diabetes and how to bring it under control with turmeric, an highly ...
Antioxidants are artificial or natural components that help protect the human body from the damage ...
Angiogenesis is the process of formation of new blood vessels from pre-existing blood vessels. It ...View All